Pharmacological treatment of pathologic aggression in children

Drew H. Barzman, Robert L Findling

Research output: Contribution to journalArticle

Abstract

Children with psychiatric illness may display pathologic aggression (PA) that is destructive, severe, chronic, and unresponsive to psychosocial and psychopharmacological treatment of their underlying condition(s) and psychosocial interventions specifically targeting PA. For this subset of children with PA, pharmacotherapy may be an appropriate treatment option to optimize their functioning. This article reviews pharmacological treatment studies for PA in children and the safety and efficacy of risperidone, olanzapine, lithium, divalproex sodium, methylphenidate, and typical antipsychotics in this patient population. While safety needs to be emphasized when prescribing medication for these patients, serious health and safety risks are also raised when PA is not effectively treated. Future research is needed to evaluate whether the long-term risks associated with the pharmacological treatment of PA outweigh the potential benefits to the child.

Original languageEnglish (US)
Pages (from-to)151-157
Number of pages7
JournalInternational Review of Psychiatry
Volume20
Issue number2
DOIs
StatePublished - Apr 2008
Externally publishedYes

Fingerprint

Aggression
Pharmacology
olanzapine
Safety
Therapeutics
Child Psychiatry
Methylphenidate
Risperidone
Valproic Acid
Lithium
Antipsychotic Agents
Drug Therapy
Health
Population

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Pharmacological treatment of pathologic aggression in children. / Barzman, Drew H.; Findling, Robert L.

In: International Review of Psychiatry, Vol. 20, No. 2, 04.2008, p. 151-157.

Research output: Contribution to journalArticle

@article{5a31b682f68845c998f38392e1af29ca,
title = "Pharmacological treatment of pathologic aggression in children",
abstract = "Children with psychiatric illness may display pathologic aggression (PA) that is destructive, severe, chronic, and unresponsive to psychosocial and psychopharmacological treatment of their underlying condition(s) and psychosocial interventions specifically targeting PA. For this subset of children with PA, pharmacotherapy may be an appropriate treatment option to optimize their functioning. This article reviews pharmacological treatment studies for PA in children and the safety and efficacy of risperidone, olanzapine, lithium, divalproex sodium, methylphenidate, and typical antipsychotics in this patient population. While safety needs to be emphasized when prescribing medication for these patients, serious health and safety risks are also raised when PA is not effectively treated. Future research is needed to evaluate whether the long-term risks associated with the pharmacological treatment of PA outweigh the potential benefits to the child.",
author = "Barzman, {Drew H.} and Findling, {Robert L}",
year = "2008",
month = "4",
doi = "10.1080/09540260801887819",
language = "English (US)",
volume = "20",
pages = "151--157",
journal = "International Review of Psychiatry",
issn = "0954-0261",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Pharmacological treatment of pathologic aggression in children

AU - Barzman, Drew H.

AU - Findling, Robert L

PY - 2008/4

Y1 - 2008/4

N2 - Children with psychiatric illness may display pathologic aggression (PA) that is destructive, severe, chronic, and unresponsive to psychosocial and psychopharmacological treatment of their underlying condition(s) and psychosocial interventions specifically targeting PA. For this subset of children with PA, pharmacotherapy may be an appropriate treatment option to optimize their functioning. This article reviews pharmacological treatment studies for PA in children and the safety and efficacy of risperidone, olanzapine, lithium, divalproex sodium, methylphenidate, and typical antipsychotics in this patient population. While safety needs to be emphasized when prescribing medication for these patients, serious health and safety risks are also raised when PA is not effectively treated. Future research is needed to evaluate whether the long-term risks associated with the pharmacological treatment of PA outweigh the potential benefits to the child.

AB - Children with psychiatric illness may display pathologic aggression (PA) that is destructive, severe, chronic, and unresponsive to psychosocial and psychopharmacological treatment of their underlying condition(s) and psychosocial interventions specifically targeting PA. For this subset of children with PA, pharmacotherapy may be an appropriate treatment option to optimize their functioning. This article reviews pharmacological treatment studies for PA in children and the safety and efficacy of risperidone, olanzapine, lithium, divalproex sodium, methylphenidate, and typical antipsychotics in this patient population. While safety needs to be emphasized when prescribing medication for these patients, serious health and safety risks are also raised when PA is not effectively treated. Future research is needed to evaluate whether the long-term risks associated with the pharmacological treatment of PA outweigh the potential benefits to the child.

UR - http://www.scopus.com/inward/record.url?scp=41749089619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41749089619&partnerID=8YFLogxK

U2 - 10.1080/09540260801887819

DO - 10.1080/09540260801887819

M3 - Article

C2 - 18386205

AN - SCOPUS:41749089619

VL - 20

SP - 151

EP - 157

JO - International Review of Psychiatry

JF - International Review of Psychiatry

SN - 0954-0261

IS - 2

ER -